Pursuant to Regulation 30 read with Schedule III of the SEBI Listing Regulations, Lupin has informed that Nanomi B.V., the Netherlands (‘Nanomi’), a wholly owned subsidiary of the Company in Netherlands has entered into a definitive agreement to acquire the entire share capital of VISUfarma B.V., headquartered in Amsterdam, the Netherlands. The details required under Regulation 30 and Schedule III of SEBI Listing Regulations, read with the SEBI Master Circular dated November 11, 2024, bearing reference number SEBI/HO/CFD/PoD2/CIR/P/0155 and such other circulars as applicable (‘SEBI Master Circular’), is set at Annexure I. A Press Release along with a brief presentation are also enclosed.
The above information is a part of company’s filings submitted to BSE.
